{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-197124","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.230389+00:00","generated_at":"2026-05-15T00:36:52.910373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M","bullets":["Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.","Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).","Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.","FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.","Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197124","json":"https://secwatch.observer/filing/0001193125-26-197124.json","markdown":"https://secwatch.observer/filing/0001193125-26-197124.md","text":"https://secwatch.observer/filing/0001193125-26-197124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/0001193125-26-197124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:36:52.910373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"671afe9c725d9fc9de05d99d55f83c8aa6a4fc53","claim":"Syndax Pharmaceuticals Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $64.9 million.","evidence_excerpt":"Syndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/0001193125-26-197124-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"Total revenue of $64.9 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}